Bioactive coatings that are stabilized against inactivation by weathering are provided including a base associated with a chemically modified enzyme, and, optionally a first polyoxyethylene present in the base and independent of the enzyme. The coatings are optionally overlayered onto a substrate to form an active coating facilitating the removal of organic stains or organic material from food, insects, or the environment.

Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of taxane-based compounds and/or fluorinated forms thereof. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the taxane-based compound is achieved.

The present invention provides a method for producing a maleimide polyethylene glycol lipid, and the method includes a reaction step of deprotecting a maleimide polyethylene glycol lipid having a protective group by heating the maleimide polyethylene glycol lipid having a protective group in a solvent in the presence of silica gel. According to the present invention, a production method of preventing deterioration of a maleimide group and improving a maleimidation rate can be provided.

Bioactive coatings are provided with two component solvent borne resin and an enzyme dispersed therein. The unique coatings provide for enzyme dispersion in the two component solvent borne resin in aggregates with small particle sizes of up to 5 micrometers. The coatings are optionally overlayered onto a substrate to form an active coating facilitating the removal of organic stains or organic material from food, insects, or the environment.

Bioactive coatings that are stabilized against inactivation by weathering are provided including a base including an enzyme associated therein, and a first polyoxyethylene present in the base and independent of the enzyme. The coatings are optionally overlayered onto a substrate to form an active coating facilitating the removal of organic stains or organic material from food, insects, or the environment.

Polymeric reagents are provided comprising a moiety of atoms arranged in a specific order, wherein the moiety is positioned between a water-soluble polymer and a reactive group. The polymeric reagents are useful for, among other things, forming polymer-active agent conjugates. Related methods, compositions, preparations, and so forth are also provided.

A method of preparing a protein conjugate contains linking a mono-PEGylated immunoglobulin Fc region to a dual agonist exhibiting activity on both GLP-1 and glucagon. The mono-PEGylated immunoglobulin Fc region is prepared by linking a linker of Formula 1 to the N-terminus of an immunoglobulin Fc region comprising a hinge sequence:

CHO-L1-(OCH.sub.2CH.sub.2).sub.nO-L2-R.  [Formula 1]

The present invention relates to tri-functional crosslinking reagents carrying (i) a ligand-reactive group for conjugation to a ligand of interest having at least one binding site on a target glycoprotein receptor, (ii) a hydrazone group for the capturing of oxidized receptor-glycoproteins and (iii) an affinity group selected from azides and alkynes for the detection, isolation and purification of captured glycoproteins; as well as their manufacturing. The invention further provides for improved methods of detecting, identifying and characterizing interactions between ligands and their corresponding target glycoproteins on living cells and in biological fluids. The invention further provides for new uses of catalysts in such methods.

The present invention provides a raw material for bulk drugs and a pharmaceutical additive which provide excellent formulation stability and excellent over-time stability of drug efficacy when used to modify a bulk drug, a polypeptide, a bioactive protein, an enzyme, and the like. The present invention relates to a raw material for bulk drugs or a pharmaceutical additive, containing: a polyether composition (A) represented by formula (1), wherein the polyether composition (A) has a unimodal molecular weight distribution, the polyether composition (A) has a ratio (Mw/Mn) of the weight average molecular weight (Mw) to the number average molecular weight (Mn) of 1.20 or less, and the polyether composition (A) contains a compound in which m is 1 in formula (1) in an amount of 90 wt % or more based on the weight of the polyether composition (A), in formula (1), OR.sup.1, R.sup.2O, R.sup.3O, and R.sup.4O are each independently a C2-C8 oxyalkylene group; when each of these moieties exists in the plural number, each OR.sup.1, each R.sup.2O, each R.sup.3O, and each R.sup.4O may be the same as or different from each other; these moieties may be bonded randomly or in block; a, b, c, and d are each independently an integer of 50 to 1200; X.sup.1 to X.sup.4 are each independently a hydrogen atom, a substituent represented by formula (2), or a substituent represented by formula (3); and m is an integer of 1 to 10. ##STR00001##

The present disclosure provides a drug carrier, a brain-targeting nanodrug based on CRISPR gene editing technology and a preparation method and use thereof. The nanodrug contains nanoparticles prepared by coupling Cas9/sgRNA and drug carriers. The drug carrier includes a polymer mPEG-P (GPMA, FPMA) and a polymer Ang-PEG-PGPMA, wherein a structural formula of the mPEG-P (GPMA, FPMA) is:

##STR00001##

a structural formula of the polymer Ang-PEG-PGPMA is:

##STR00002##

where n is 35-45, x1 is 15-20, y is 2-4, m is 75-85, and x2=x1. The guanidino group of the drug carrier can be combined with the ribonucleoprotein complex by electrostatic action, salt bridge formation, or hydrogen bonding action. Also provided are methods of suppressing and treating tumors at a gene level using the drug carrier to transport the therapeutic drug to the lesion site.